Overview
Adapting to Regulatory Evolution: Join Us at the UK National QPPV Forum!
The Windsor Framework officially came into effect in January 2025, and as professionals—from pharma companies, regulatory bodies, consultants, and auditors—you are now in the process of implementing it. As you navigate this transition, it’s crucial to share experiences and seek expert guidance on the implementation process. This forum provides a unique opportunity to address the challenges you’ve encountered in the initial months of rollout.
At this year's forum, we will facilitate meaningful discussions on practical issues, including small group sessions where you can ask questions and receive targeted solutions to your specific challenges. As the national UK landscape continues to evolve, this forum will also provide updates on key developments, including:
- Windsor Framework – Implementation strategies
- MHRA – Inspection priorities
- Clinical Trial Regulation (CTACR) & Post-Market Surveillance (PMS) – Latest updates for medical devices
- AI in Device Vigilance – Opportunities & challenges
Engage in expert-led breakout discussions, gain insights from MHRA representatives, and leave with actionable compliance strategies.
Don't miss this opportunity to stay informed & prepared!
Program Committee
-
Elspeth McIntosh, MBA, RN Director
Castle Pharmacovigilance Ltd, United Kingdom -
Sophie Radicke, MSc Head of GPvP and Senior Pharmacovigilance Inspector
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Louise Woodward, PhD UK QPPV and Local Safety Responsible
Roche Products Ltd, United Kingdom -
Helen Fiddes Head of Country Pharmacovigilance, UK and Ireland
Bristol-Myers Squibb, United Kingdom -
Lauren East Head, Pharmacovigilance UK
Abbvie, United Kingdom -
Claudia Ferreira Scientific Programs Manager
DIA, Switzerland
Have an account?